The medical community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s exhibiting significant promise in clinical trials for addressing obesity. Unlike some existing weight loss solutions, retatrutide appears to deliver a significant substantial loss in body size and enhance metabolic markers, particula